Topic: Advances in Cancer Immunotherapy

By integrating cutting-edge approaches such as immunogenomics, single-cell profiling, spatial transcriptomics, and AI-driven predictive modeling, we aim to dissect immune evasion mechanisms, enhance therapeutic efficacy, and address challenges such as resistance and toxicity.

We will explore how novel immunotherapies—including checkpoint inhibitors, CAR-T/NK cell therapies, cancer vaccines, and bispecific antibodies—are reshaping oncology, with a strong focus on translating preclinical insights into clinically actionable solutions.

We welcome submissions in various formats, including Original Research, Reviews, Clinical Trials, Case Studies, Perspectives, and Commentaries, on topics such as:
● Next-generation immune checkpoint inhibitors and combination strategies to overcome resistance;
● Engineering CAR-T/NK cells for improved specificity, persistence, and safety;
● Tumor microenvironment dynamics and strategies to enhance immune infiltration;
● Predictive biomarkers for patient stratification and response monitoring;
● Epigenetic and metabolic reprogramming of immune-tumor interactions;
● Neoantigen discovery and personalized cancer vaccine development;
● Microbiome modulation to enhance immunotherapy outcomes;
● AI/ML applications in immune-targeted therapy design and resistance prediction;
● Immunotherapy for rare cancers and underrepresented patient populations;
● Strategies to mitigate immune-related adverse events and optimize treatment schedules;
● Regulatory T cell targeting and myeloid cell remodeling for enhanced responses;
● Translational challenges in scaling engineered cell therapies and cost-effective manufacturing;
● The synergy of immunotherapy and tissue engineering for cancer management.

Cancer immunotherapy, immune checkpoint inhibitors, CAR-T cells, tumor microenvironment, immune resistance, neoantigens, microbiome, precision oncology, adoptive cell therapy

31 Oct 2025